[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-381986-105":59,"doc-detail-381986-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","risk-of-venous-thromboembolism-in-pregnant-patients-with-active-malignancy-systematic-review-and-meta-analysis","Risk of venous thromboembolism in pregnant patients with active malignancy - systematic review and meta-analysis","","This systematic review and meta-analysis evaluates the rate of venous thromboembolism (VTE) in pregnant patients with active malignancy versus pregnant patients without malignancy. Searches covered Embase, Medline/PubMed, Cochrane, and trial databases from inception to June 2021, restricted to English and French human studies. Seven cohort studies (5928 individuals) showed active malignancy significantly increased VTE odds (OR 6.8, 95% CI 3.8–12.1), with elevated risks varying by cancer type, while absolute VTE risk was 0.9% versus 0.2%.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/risk-of-venous-thromboembolism-in-pregnant-patients-with-active-malignancy-systematic-review-and-meta-analysis/381986/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/risk-of-venous-thromboembolism-in-pregnant-patients-with-active-malignancy-systematic-review-and-meta-analysis/381986.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main objective?","Question",{"text":112,"@type":113},"To evaluate the rate of VTE in pregnant patients with active malignancy compared with pregnant patients without malignancy, and to consider the role of thromboprophylaxis in this population.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the literature searched and which studies were included?",{"text":117,"@type":113},"Databases including Embase, Medline/PubMed, Cochrane, and clinical trial sources were searched from inception to June 2021. A total of 3821 articles were screened, and seven cohort studies reporting VTE rates were included.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the meta-analysis find about VTE risk?",{"text":121,"@type":113},"Active malignancy in pregnancy significantly increased VTE odds (OR 6.8, 95% CI 3.8–12.1). Absolute VTE risk was 0.9% with active malignancy versus 0.2% without active malignancy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},381986,1790641127,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","DOI: 10. 1111/aogs.14712  \nSYS T E MAT I C R E VI E W  \nRisk of venous thromboembolism in pregnant patients with active malignancy: A systematic review and meta-analysis  \nSara Folkins1 | Ashley Miller2 | Christopher M. Nash3   \n1Dalhousie University Medical School, Halifax, Nova Scotia, Canada 2Division of General Internal Medicine, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada 3 Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Dalhousie University, Halifax, Nova Scotia, Canada  \nCorrespondence  \nChristopher M. Nash, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Dalhousie University, 5850/5980 University Avenue, Halifax, NS B3K 6R8, Canada.  \nEmail: [cmnash@dal.ca](cmnash@dal.ca)  \nAbstract  \nIntroduction: Cancer currently occurs in about 1 in 1000 pregnancies. Both active malignancy and pregnancy are individual risk factors for venous thromboembolism (VTE) . The purpose of this systematic review/meta-analysis was to evaluate the rate of VTE in pregnant patients with active malignancy compared with pregnant patients without malignancy.  \nMaterial and methods: Embase, Medline/PubMed, Cochrane Database, and clinical[trial.gov](trial.gov) were search by a trained librarian from inception until June 2021, and limited to English and French language human studies using keywords related to pregnancy, neoplasm, and thrombosis. This study was prospectively registered with PROSPERO (CRD42021245886) . Title, abstract, and full-text review was performed using the Covidence data management system. Two authors reviewed the studies independently. Of the 3821 articles screened, seven cohort studies were included that reported VTE rate in patients with active malignancy in pregnancy.  \nResults: A total of 5928 individuals had active malignancy and pregnancy. Active malignancy in pregnancy significantly increased the odds of a VTE (odds ratio [OR] 6. 8, 95% confidence interval [CI] 3 .8–12. 1) . Specifically, patients with thyroid (OR 2 .7, 95% CI 1.3–6. 3), cervix (OR 6 . 6, 95% CI 2 .4–18.0), or other gynecological (OR 10 . 6, 95% CI 4.4–25. 8) cancers; Hodgkin's lymphoma (OR 8 .7, 95% CI 3.3–23.4); or acute leukemia (OR 17. 1, 95% CI 10.9–26. 8) all had increased odds, whereas those with brain cancer (OR 6. 1, 95% CI 0.4–98. 2), breast cancer (OR 2. 5, 95% CI 0.3–17.4), malignant melanoma (OR 5. 5, 95% CI 0.3–88. 1), or non-Hodgkin's lymphoma (OR 3. 2, 95% CI 0.8– 12.9) malignancies did not have statistically significant increased odds for VTE. No studies reported whether prophylactic anticoagulation was used during pregnancy in this population; nor did they report timing in pregnancy of the VTE. The absolute risk for VTE in those with active malignancy was 0.9% compared with 0. 2% in those without active malignancy in pregnancy.  \n\n| Abbreviations: CI, confidence interval; HCUP-NIS, Health Care Cost and Utilization Project—Nationwide Inpatient sample; LMWH, low-molecular-weight heparin; OR, odds ratio; VTE, venous thromboembolism. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.\u003Cbr>© 2023 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG) . |\n\nActa Obstet Gynecol Scand. 2024;103:645–[652.](652. wileyonlinelibrary.com/journal/aogs | 645)[ wileyonlinelibrary.com/journal/aogs](652. wileyonlinelibrary.com/journal/aogs | 645)[ |](652. wileyonlinelibrary.com/journal/aogs | 645)[ 645](652. wileyonlinelibrary.com/journal/aogs | 645)  \n646  \n FOLKINS et al.  \nConclusions: Pregnancy with active malignancy confers a significant increased risk for VTE compared with pregnancy alone. Given this finding, prophylactic anticoagula","cbCaieVQc8WpFRRe","https://ap.wps.com/l/cbCaieVQc8WpFRRe","pdf",1894052,"English","# Introduction\n## Risk factors and clinical background\n# Material and methods\n## Search strategy and study selection\n# Results\n## VTE odds by cancer type and absolute risk\n# Conclusions","[{\"question\":\"What is the study’s main objective?\",\"answer\":\"To evaluate the rate of VTE in pregnant patients with active malignancy compared with pregnant patients without malignancy, and to consider the role of thromboprophylaxis in this population.\"},{\"question\":\"How was the literature searched and which studies were included?\",\"answer\":\"Databases including Embase, Medline/PubMed, Cochrane, and clinical trial sources were searched from inception to June 2021. A total of 3821 articles were screened, and seven cohort studies reporting VTE rates were included.\"},{\"question\":\"What did the meta-analysis find about VTE risk?\",\"answer\":\"Active malignancy in pregnancy significantly increased VTE odds (OR 6.8, 95% CI 3.8–12.1). Absolute VTE risk was 0.9% with active malignancy versus 0.2% without active malignancy.\"}]","Risk of venous thromboembolism in pregnant patients with active malignancy - systematic review and meta-analysis | PDF",1790248324]